☀️ Wake-Promoting Agent Cardiovascular Monitoring Simulator

Baseline Vitals Before Therapy Begins

Every wake-promoting agent course starts with a clean cardiovascular baseline.

• 118: Normal resting SBP (mmHg, adult average)
• 68: Normal resting HR (bpm, adult average)
• ~1 in 2,000: Narcolepsy prevalence (US population)
• Yes: Baseline ECG required (before first dose)

Why baseline matters

A pre-treatment reading anchors every later comparison.

Clinicians log blood pressure, heart rate, and rhythm.

Any undiagnosed hypertension surfaces before drug exposure.

Who gets screened

Patients with cardiac history get extra scrutiny.

Blood pressure over 140/90 delays treatment start.

Baseline weight and heart rhythm are also noted.

Setting the therapeutic window

Baseline values define a safe upper monitoring bound.

Deviation from this bound triggers a clinical review.

Solriamfetol and Modafinil Dosing

Wake-promoting agents are taken once daily to manage excessive sleepiness.

• 75–150 mg: Solriamfetol dose range (once daily, morning)
• 100–400 mg: Modafinil dose range (once daily, morning)
• 2–4 hrs: Time to peak plasma (both agents)
• Dopamine/NE reuptake: Mechanism class (sympathomimetic-adjacent)

How the drugs act

Solriamfetol boosts dopamine and norepinephrine signaling.

Modafinil promotes wakefulness through a broader network.

Both carry mild sympathomimetic cardiovascular effects.

Dose titration

Therapy starts low and increases gradually if tolerated.

Each step-up warrants a fresh vitals check.

Absorption timing

Peak drug levels align with peak cardiac effect.

Monitoring soon after dosing catches early changes.

Sympathomimetic Effect on the Cardiovascular System

Increased catecholamine tone raises heart rate and blood pressure slightly.

• +2–5 mmHg: Typical SBP rise (standard dose)
• +3–8 bpm: Typical HR rise (standard dose)
• Up to +10: High-dose SBP rise (mmHg reported)
• ~1–2 hrs: Onset of effect (post-dose)

Mild sympathetic activation

Norepinephrine tone increases vascular tone and heart rate.

Most patients see only a small, tolerable shift.

Dose-dependent magnitude

Higher doses produce proportionally larger vital sign shifts.

High-dose patients need closer early monitoring.

Individual variability

Response varies with age, weight, and cardiac history.

Some patients show negligible change at any dose.

Ongoing Monitoring During Long-Term Treatment

Periodic vitals checks catch drift long before it becomes dangerous.

• Every 4–8 wks: Recommended check interval (first 6 months)
• Encouraged: Home BP monitoring (for high-dose patients)
• Months to years: Long-term therapy duration (chronic narcolepsy)
• 3+: Visits before dose lock-in (stable readings needed)

Scheduled rechecks

Vitals are rechecked at each follow-up appointment.

Trends across visits matter more than single readings.

Home monitoring role

Patients log home readings between clinic visits.

This fills gaps and flags early sustained drift.

Trend over single values

One elevated reading rarely changes therapy alone.

A rising multi-week trend prompts closer review.

Flagging Sustained Cardiovascular Elevation

Persistent elevation past six weeks triggers dose or referral decisions.

• ≥138 mmHg: Risk SBP threshold (sustained reading)
• ≥98 bpm: Risk HR threshold (sustained reading)
• ≥6 weeks: Sustained window (before flag triggers)
• Dose cut or cardiology: Referral outcome (clinical pathways)

Threshold crossing

Two consecutive elevated readings raise a formal flag.

The flag prompts a documented clinical decision.

Dose adjustment path

Lowering the dose often resolves mild elevation.

Vitals are rechecked after each adjustment.

Cardiology referral path

Persistent elevation despite dose cuts warrants referral.

A cardiologist evaluates ongoing therapy suitability.